US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US6541606B2
(en)
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
JP4317010B2
(ja)
|
2001-07-25 |
2009-08-19 |
ピーディーエル バイオファーマ,インコーポレイティド |
IgG抗体の安定な凍結乾燥医薬製剤
|
EP3192528A1
(en)
|
2002-02-14 |
2017-07-19 |
Chugai Seiyaku Kabushiki Kaisha |
Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
|
US20040042972A1
(en)
|
2002-04-11 |
2004-03-04 |
Medimmune Vaccines, Inc. |
Spray freeze dry of compositions for intranasal administration
|
AU2003247337B2
(en)
|
2002-04-11 |
2007-09-06 |
Medimmune, Llc |
Preservation of bioactive materials by freeze dried foam
|
EP1572915A4
(en)
|
2002-04-11 |
2011-01-05 |
Medimmune Vaccines Inc |
PRESERVATION OF BIOACTIVE MATERIALS BY SPRAY DRYING
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
AU2011226771B2
(en)
|
2002-06-14 |
2012-10-04 |
Medimmune, Llc |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
JP2005532395A
(ja)
|
2002-07-02 |
2005-10-27 |
スミスクライン・ビーチャム・コーポレイション |
新規な安定処方
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
US7055598B2
(en)
|
2002-08-26 |
2006-06-06 |
Halliburton Energy Services, Inc. |
Fluid flow control device and method for use of same
|
WO2004019860A2
(en)
|
2002-08-28 |
2004-03-11 |
Pharmacia Corporation |
Formulations of modified antibodies and methods of making the same
|
WO2004039337A2
(en)
|
2002-10-31 |
2004-05-13 |
Protein Design Labs, Inc. |
Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
|
US20040191243A1
(en)
|
2002-12-13 |
2004-09-30 |
Bei Chen |
System and method for stabilizing antibodies with histidine
|
EP1578394A4
(en)
|
2002-12-31 |
2011-02-23 |
Nektar Therapeutics |
ANTIBODY PARTICLES AND COMPOSITIONS
|
US20040208869A1
(en)
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
PT1610820E
(pt)
|
2003-04-04 |
2010-12-16 |
Novartis Ag |
Formulações de elevada concentração de anticorpos e proteínas
|
EA009285B1
(ru)
|
2003-05-14 |
2007-12-28 |
Иммуноджен, Инк. |
Композиция конъюгированного лекарственного средства
|
PT1631313E
(pt)
|
2003-06-05 |
2015-07-02 |
Genentech Inc |
Terapêutica de combinação para distúrbios de células b
|
CN100531813C
(zh)
|
2003-08-12 |
2009-08-26 |
伊莱利利公司 |
具有实现机械利益的三头螺纹的药物分配装置
|
JP4219932B2
(ja)
|
2003-10-01 |
2009-02-04 |
協和発酵キリン株式会社 |
抗体の安定化方法及び安定化された溶液状抗体製剤
|
AR046639A1
(es)
|
2003-11-21 |
2005-12-14 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti- igfr1
|
WO2005065709A2
(de)
|
2003-12-24 |
2005-07-21 |
Boehringer Ingelheim International Gmbh |
Gefriergetrocknete formulierung von antikörperkonjugaten
|
JPWO2005063291A1
(ja)
|
2003-12-25 |
2007-07-19 |
麒麟麦酒株式会社 |
抗体を含有する安定な水性医薬製剤
|
AR048098A1
(es)
|
2004-03-15 |
2006-03-29 |
Wyeth Corp |
Conjugados de caliqueamicina
|
JP4874233B2
(ja)
|
2004-03-30 |
2012-02-15 |
イーライ リリー アンド カンパニー |
最終用量の投与によって可能になるバネ駆動固定の特徴を持つ薬剤投与器具
|
AU2005249360B2
(en)
|
2004-04-12 |
2011-07-21 |
Medimmune, Llc |
Anti-IL-9 antibody formulations and uses thereof
|
US8658203B2
(en)
|
2004-05-03 |
2014-02-25 |
Merrimack Pharmaceuticals, Inc. |
Liposomes useful for drug delivery to the brain
|
US20070196364A1
(en)
|
2004-07-27 |
2007-08-23 |
Human Genome Sciences, Inc. |
Pharmaceutical Formulation and Process
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
JP2008521411A
(ja)
|
2004-11-30 |
2008-06-26 |
キュラジェン コーポレイション |
Gpnmbに対する抗体およびその使用
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
EA015584B1
(ru)
|
2005-03-23 |
2011-10-31 |
Генмаб А/С |
Антитело к cd38 человека и его применение
|
CN101166763B
(zh)
|
2005-04-18 |
2012-09-19 |
伊达研究和发展有限公司 |
稳定的抗乙肝病毒(hbv)抗体配制剂
|
KR101539545B1
(ko)
|
2005-06-07 |
2015-07-24 |
에스바테크 - 어 노바티스 컴파니 엘엘씨 |
TNFα를 억제하는 안정적이고 가용성인 항체
|
JP2008543839A
(ja)
*
|
2005-06-14 |
2008-12-04 |
アムジェン インコーポレーテッド |
自己緩衝タンパク質製剤
|
EP1896505A2
(en)
|
2005-06-15 |
2008-03-12 |
Schering Corporation |
Anti-igf1r antibody formulations
|
WO2007002543A2
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
NZ623901A
(en)
|
2005-08-03 |
2015-10-30 |
Immunogen Inc |
Immunoconjugate formulations
|
AU2006295340B2
(en)
|
2005-08-05 |
2010-11-11 |
Amgen Inc. |
Stable aqueous protein or antibody pharmaceutical formulations and their preparation
|
EP3037544A1
(en)
|
2005-10-13 |
2016-06-29 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
|
DOP2005000210A
(es)
|
2005-10-19 |
2006-04-30 |
Genentech Inc |
Antibony formulations
|
US20070172520A1
(en)
|
2005-11-18 |
2007-07-26 |
University Of South Florida |
Immunotargeting of Nonionic Surfactant Vesicles
|
KR20080071192A
(ko)
|
2005-11-22 |
2008-08-01 |
와이어쓰 |
면역글로불린 융합 단백질 제형
|
SI1963368T1
(sl)
*
|
2005-12-13 |
2012-11-30 |
Lilly Co Eli |
Anti il protitelesa
|
AU2006330858A1
(en)
|
2005-12-21 |
2007-07-05 |
Wyeth |
Protein formulations with reduced viscosity and uses thereof
|
EP1977763A4
(en)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
STABILIZER PREPARATION CONTAINING ANTIBODIES
|
HUE049832T2
(hu)
|
2005-12-29 |
2020-10-28 |
Janssen Biotech Inc |
Humán anti-IL-23 ellenanyagok, készítmények, eljárás és alkalmazások
|
JP2009525986A
(ja)
|
2006-02-03 |
2009-07-16 |
メディミューン,エルエルシー |
タンパク質製剤
|
CA2642270A1
(en)
|
2006-02-15 |
2007-08-23 |
Imclone Systems Incorporated |
Antibody formulation
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
AU2007240732B2
(en)
|
2006-04-21 |
2013-07-04 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
EP2029163A4
(en)
|
2006-06-14 |
2010-08-11 |
Imclone Llc |
LYOPHILIZED FORMULATIONS OF ANTI-EGFR ANTIBODIES
|
TW200826974A
(en)
|
2006-09-07 |
2008-07-01 |
Kirin Pharma Kk |
Stable lyophilized pharmaceutical preparation comprising antibody
|
WO2008039761A2
(en)
|
2006-09-25 |
2008-04-03 |
Medimmune, Llc. |
Stabilized antibody formulations and uses thereof
|
MX2009003635A
(es)
|
2006-10-06 |
2009-04-22 |
Amgen Inc |
Formulaciones de anticuerpos estables.
|
ES2925992T3
(es)
|
2006-10-20 |
2022-10-20 |
Amgen Inc |
Formulaciones estables de polipéptidos
|
DE102006053375A1
(de)
|
2006-11-10 |
2008-05-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Mischung von Pulvern
|
EP2094729A1
(en)
|
2006-12-11 |
2009-09-02 |
F.Hoffmann-La Roche Ag |
Abeta antibody parenteral formulation
|
ES2748526T3
(es)
|
2006-12-21 |
2020-03-17 |
Amgen Inc |
Formulaciones tamponadas estables que contienen polipéptidos
|
CA2674608A1
(en)
|
2007-01-09 |
2008-07-17 |
Wyeth |
Anti-il-13 antibody formulations and uses thereof
|
JP5478261B2
(ja)
|
2007-01-11 |
2014-04-23 |
ノヴォ ノルディスク アクティーゼルスカブ |
抗kir抗体、製剤、およびその使用
|
CA2681743A1
(en)
|
2007-03-22 |
2008-09-25 |
Imclone Llc |
Stable antibody formulations
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
TW200909005A
(en)
*
|
2007-06-14 |
2009-03-01 |
Elan Pharm Inc |
Lyophilized immunoglobulin formulations and methods of preparation
|
US20090208492A1
(en)
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
US20110014676A1
(en)
|
2007-06-29 |
2011-01-20 |
Battelle Memorial Institute |
Protein stabilization
|
WO2009015345A1
(en)
|
2007-07-25 |
2009-01-29 |
Amgen Inc. |
Pharmaceutical compositions comprising fc fusion proteins
|
US8796206B2
(en)
|
2007-11-15 |
2014-08-05 |
Amgen Inc. |
Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
WO2009073569A2
(en)
|
2007-11-30 |
2009-06-11 |
Abbott Laboratories |
Protein formulations and methods of making same
|
WO2009120684A1
(en)
|
2008-03-25 |
2009-10-01 |
Medimmune, Llc |
Antibody formulation
|
WO2009141239A1
(en)
|
2008-05-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
|
EP2324315A2
(en)
|
2008-06-26 |
2011-05-25 |
Wyeth LLC |
Lyophilization cycle robustness strategy
|
WO2010017296A1
(en)
|
2008-08-05 |
2010-02-11 |
Wyeth |
Lyophilization above collapse
|
MX2011002159A
(es)
|
2008-08-27 |
2011-03-29 |
Schering Corp |
Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria.
|
CN102159194A
(zh)
|
2008-09-19 |
2011-08-17 |
霍夫曼-拉罗奇有限公司 |
新抗体制剂
|
HUE036126T2
(hu)
|
2008-09-19 |
2018-06-28 |
Pfizer |
Stabil folyékony ellenanyag kiszerelés
|
WO2010042705A1
(en)
|
2008-10-09 |
2010-04-15 |
Medimmune, Llc |
Antibody formulation
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン,エルエルシー |
抗体製剤
|
WO2010057109A1
(en)
|
2008-11-17 |
2010-05-20 |
Genentech, Inc. |
Method and formulation for reducing aggregation of a macromolecule under physiological conditions
|
MX2011005051A
(es)
|
2008-11-17 |
2011-06-01 |
Genentech Inc |
Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas.
|
EP2358393A1
(en)
|
2008-11-20 |
2011-08-24 |
F.Hoffmann-La Roche Ag |
Therapeutic protein formulations
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
RU2011126338A
(ru)
|
2008-11-28 |
2013-01-10 |
Эбботт Лэборетриз |
Стабильные композиции антител и способы их стабилизации
|
JP2012511531A
(ja)
*
|
2008-12-09 |
2012-05-24 |
エフ.ホフマン−ラ ロシュ アーゲー |
賦形剤不含抗体溶液を得るための方法
|
EP2196476A1
(en)
*
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
WO2010069858A1
(en)
|
2008-12-19 |
2010-06-24 |
F. Hoffmann-La Roche Ag |
Pharmaceutical composition
|
FR2944448B1
(fr)
|
2008-12-23 |
2012-01-13 |
Adocia |
Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
|
JP5836807B2
(ja)
|
2009-03-05 |
2015-12-24 |
アッヴィ・インコーポレイテッド |
Il−17結合タンパク質
|
AR075715A1
(es)
|
2009-03-05 |
2011-04-20 |
Novartis Ag |
Formulacion de anticuerpo liofilizado
|
WO2010100135A1
(en)
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
AU2010221099A1
(en)
|
2009-03-06 |
2011-09-22 |
Medimmune, Llc |
Humanized anti-CD19 antibody formulations
|
KR101675412B1
(ko)
|
2009-03-31 |
2016-11-11 |
덴카 세이켄 가부시키가이샤 |
면역 분석 방법 및 그것을 위한 시약
|
JP2010241718A
(ja)
|
2009-04-03 |
2010-10-28 |
Kyowa Hakko Kirin Co Ltd |
安定な抗体の水溶液製剤
|
US20100322943A1
(en)
|
2009-06-17 |
2010-12-23 |
Thomas Cantor |
Therapeutic and diagnostic affinity purified specific polyclonal antibodies
|
RU2011151286A
(ru)
|
2009-06-18 |
2013-07-27 |
УАЙТ ЭлЭлСи |
Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств
|
WO2010148321A1
(en)
|
2009-06-18 |
2010-12-23 |
Wyeth Llc |
Slow dissolution method for reconstitution of lyophilized material
|
WO2011008770A2
(en)
|
2009-07-14 |
2011-01-20 |
Biogen Idec Ma Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
EP2458990B1
(en)
|
2009-07-28 |
2016-03-30 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
WO2011028962A1
(en)
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody coformulations
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
EP3721904B1
(en)
|
2009-11-20 |
2021-10-13 |
Biocon Limited |
Formulations of t1h antibody
|
CN102686241A
(zh)
|
2009-12-29 |
2012-09-19 |
霍夫曼-拉罗奇有限公司 |
抗体配制剂
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
PL2523688T3
(pl)
|
2010-01-15 |
2018-04-30 |
Kirin-Amgen, Inc. |
Formulacja przeciwciała i reżimy terapeutyczne
|
KR101419160B1
(ko)
|
2010-03-01 |
2014-07-11 |
일라이 릴리 앤드 캄파니 |
이중 기능 편위 부재를 포함하는 지연 기구를 구비한 자동 주입 장치
|
EP2542221A4
(en)
|
2010-03-01 |
2013-10-23 |
Cytodyn Inc |
CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
BR112012023895A2
(pt)
|
2010-03-17 |
2016-11-29 |
Abbott Res Bv |
composições de anti-fator de crescimento do nervo (ngf)
|
RU2600847C2
(ru)
|
2010-05-10 |
2016-10-27 |
Интас Биофармасьютикалс Лимитед |
Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
|
HUE033315T2
(en)
|
2010-05-14 |
2017-11-28 |
Amgen Inc |
High concentration antibody preparations
|
EP2399604A1
(en)
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Novel antibody formulation
|
JP2013531679A
(ja)
|
2010-07-02 |
2013-08-08 |
メディミューン,エルエルシー |
抗体製剤
|
JOP20190250A1
(ar)
|
2010-07-14 |
2017-06-16 |
Regeneron Pharma |
صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
|
FR2962650B1
(fr)
|
2010-07-19 |
2013-04-05 |
Lab Francais Du Fractionnement |
Composition d'immunoglobulines humaines concentrees
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
EP2616814A1
(en)
|
2010-09-17 |
2013-07-24 |
AbbVie Inc. |
Raman spectroscopy for bioprocess operations
|
EP3354280B1
(en)
|
2010-10-06 |
2020-07-29 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
|
DE20187001T1
(de)
|
2010-11-05 |
2021-04-01 |
Novartis Ag |
Verfahren zur behandlung von psoriasus-arthritis mit il-17 antagonisten
|
EP2637690B1
(en)
|
2010-11-11 |
2016-09-21 |
AbbVie Biotechnology Ltd |
HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
|
WO2012068549A2
(en)
|
2010-11-19 |
2012-05-24 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
US9458240B2
(en)
|
2010-12-10 |
2016-10-04 |
Novartis Pharma Ag |
Anti-BAFFR antibody formulations
|
EP2471554A1
(en)
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmaceutical formulation comprising a biopharmaceutical drug
|
EP2500035A1
(en)
|
2011-03-15 |
2012-09-19 |
Icon Genetics GmbH |
Pharmaceutical formulation containing immunglobulin
|
AR085911A1
(es)
|
2011-03-16 |
2013-11-06 |
Sanofi Sa |
Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
|
MX341076B
(es)
|
2011-03-31 |
2016-08-04 |
Merck Sharp & Dohme |
Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
|
ME02858B
(me)
|
2011-05-02 |
2018-04-20 |
Millennium Pharm Inc |
Formulacija za anti- 4 7 antitelo
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
KR20140045440A
(ko)
|
2011-06-30 |
2014-04-16 |
제넨테크, 인크. |
항-c-met 항체 제제
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
KR102196009B1
(ko)
|
2011-10-25 |
2021-01-04 |
프로테나 바이오사이언시즈 리미티드 |
항체 제형 및 방법
|
KR20140084078A
(ko)
|
2011-10-31 |
2014-07-04 |
제넨테크, 인크. |
항체 제제
|
US20140335084A1
(en)
|
2011-12-06 |
2014-11-13 |
Hoffmann-La Roche Inc. |
Antibody formulation
|
UY34542A
(es)
|
2011-12-23 |
2013-07-31 |
Mersana Therapeutics Inc |
?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
|
JP6113756B2
(ja)
|
2012-01-23 |
2017-04-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
抗ang2抗体を含有する安定化製剤
|
UA114620C2
(uk)
*
|
2012-03-07 |
2017-07-10 |
Елі Ліллі Енд Компані |
Фармацевтична композиція, яка містить анти-il-17-антитіло
|
CA2866692A1
(en)
|
2012-03-07 |
2013-07-11 |
Cadila Healthcare Limited |
Formulations which prevent formation of antibody aggregates
|
EP3662967B1
(en)
|
2012-03-07 |
2021-11-10 |
DEKA Products Limited Partnership |
Infusion pump assembly
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
EP2849723B1
(en)
|
2012-05-18 |
2018-05-02 |
Genentech, Inc. |
High-concentration monoclonal antibody formulations
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
EP2863951A1
(en)
|
2012-06-12 |
2015-04-29 |
Boehringer Ingelheim International GmbH |
Pharmaceutical formulation for a therapeutic antibody
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
US9803010B2
(en)
|
2012-06-27 |
2017-10-31 |
Merck Sharp & Dohme Corp. |
Crystalline anti-human IL-23p19 antibodies
|
US20140227250A1
(en)
|
2012-08-23 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to tslp
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
PE20191815A1
(es)
*
|
2012-09-07 |
2019-12-27 |
Coherus Biosciences Inc |
Formulaciones acuosas estables de adalimumab
|
JP2015536934A
(ja)
|
2012-10-25 |
2015-12-24 |
メディミューン,エルエルシー |
安定した低粘度の抗体製剤
|
EP2727602A1
(en)
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
EP2914289B1
(en)
|
2012-10-31 |
2019-05-22 |
Takeda GmbH |
Lyophilized formulation comprising gm-csf neutralizing compound
|
TW202033215A
(zh)
|
2012-11-01 |
2020-09-16 |
美商艾伯維有限公司 |
穩定雙重可變區域免疫球蛋白蛋白質調配物
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
EP2931311A4
(en)
|
2012-12-13 |
2016-08-17 |
Merck Sharp & Dohme |
LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
|
US9844594B2
(en)
|
2012-12-18 |
2017-12-19 |
Merck Sharp & Dohme Corp. |
Liquid formulations for an anti-TNF α antibody
|
EP2934582B1
(en)
|
2012-12-21 |
2019-11-27 |
Glenmark Pharmaceuticals S.A. |
Anti her2 antibody formulation
|
WO2014124227A1
(en)
|
2013-02-07 |
2014-08-14 |
Immunomedics, Inc. |
Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
|
ES2858472T3
(es)
|
2013-03-11 |
2021-09-30 |
Amgen Inc |
Formulaciones proteínicas
|
EP3744345B1
(en)
|
2013-03-13 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
KR20210024245A
(ko)
|
2013-03-13 |
2021-03-04 |
시애틀 지네틱스, 인크. |
사이클로덱스트린 및 항체-약물 포합체 제형
|
US11433029B2
(en)
|
2013-03-15 |
2022-09-06 |
Takeda Pharmaceutical Company Limited |
Formulation of an antibody and use thereof
|
US20160002342A1
(en)
|
2013-03-15 |
2016-01-07 |
Xinghang Ma |
Anti-prolactin receptor antibody formulations
|
DK2968588T3
(en)
|
2013-03-15 |
2019-04-23 |
Abbvie Deutschland |
ANTI-EGFR ANTIBODY CONJUGATE PHARMACEUTICAL FORMULATIONS
|
WO2014141152A2
(en)
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Low concentration antibody formulations
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
TWI679019B
(zh)
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗il-4/抗il-13之雙特異性抗體調配物
|
BR112015030501A2
(pt)
|
2013-06-04 |
2017-07-25 |
Vyome Biosciences Pvt Ltd |
partículas revestidas e composições que compreendem as mesmas
|
WO2014202775A1
(en)
|
2013-06-21 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
EP3808338A1
(en)
|
2013-09-11 |
2021-04-21 |
Eagle Biologics, Inc. |
Liquid protein formulations containing ionic liquids
|
MA38960A1
(fr)
|
2013-09-27 |
2017-10-31 |
Genentech Inc |
Formulations d'anticorps anti-pdl1
|
SG10201803178UA
(en)
|
2013-10-24 |
2018-05-30 |
Astrazeneca Ab |
Stable, aqueous antibody formulations
|
WO2015075201A1
(en)
|
2013-11-21 |
2015-05-28 |
Genmab A/S |
Antibody-drug conjugate lyophilised formulation
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
US20150225479A1
(en)
|
2014-02-12 |
2015-08-13 |
Sanofi |
Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
|
WO2015134406A1
(en)
|
2014-03-03 |
2015-09-11 |
La Jolla Biologics, Inc. |
Stable aqueous recombinant protein formulations
|
US20150291689A1
(en)
|
2014-03-09 |
2015-10-15 |
Abbvie, Inc. |
Compositions and Methods for Treating Rheumatoid Arthritis
|
US10414816B2
(en)
|
2014-03-11 |
2019-09-17 |
Green Cross Holdings Corporation |
Method for purifying immunoglobulin
|
US10287315B2
(en)
|
2014-03-11 |
2019-05-14 |
Green Cross Holdings Corporation |
Method for purifying immunoglobulin
|
TW201623331A
(zh)
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
EP3126392B1
(en)
|
2014-03-31 |
2019-09-11 |
Kirin-Amgen, Inc. |
Methods of treating nail and scalp psoriasis
|
EP3125928A4
(en)
|
2014-04-02 |
2017-11-29 |
Intas Pharmaceuticals Ltd. |
Liquid pharmaceutical composition of adalimumab
|
JP2017512814A
(ja)
|
2014-04-07 |
2017-05-25 |
シアトル ジェネティックス, インコーポレイテッド |
抗cd19抗体および抗体−薬物結合体のための安定な製剤
|
JP2015209384A
(ja)
|
2014-04-24 |
2015-11-24 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
医薬製剤
|
JP6634394B2
(ja)
|
2014-06-26 |
2020-01-22 |
アムジェン インコーポレイテッド |
タンパク質製剤
|
WO2016025911A1
(en)
|
2014-08-14 |
2016-02-18 |
Brown University |
Compositions for stabilizing and delivering proteins
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
SG11201701458YA
(en)
|
2014-09-03 |
2017-03-30 |
Medimmune Ltd |
Stable anti-il-4r-alpha antibody formulation
|
CA2959545A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
GB201416960D0
(en)
|
2014-09-25 |
2014-11-12 |
Antikor Biopharma Ltd |
Biological materials and uses thereof
|
CA2964470A1
(en)
|
2014-10-17 |
2016-04-21 |
Amgen Inc. |
Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
|
RU2017111228A
(ru)
*
|
2014-10-18 |
2018-11-21 |
Пфайзер Инк. |
Композиции антитела против IL-7R
|
TWI705827B
(zh)
|
2014-11-07 |
2020-10-01 |
瑞士商諾華公司 |
治療眼部疾病之方法
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
WO2016103093A1
(en)
|
2014-12-23 |
2016-06-30 |
Pfizer Inc. |
Stable aqueous antibody formulation for anti tnf alpha antibodies
|
EP3240571A4
(en)
|
2014-12-31 |
2018-06-13 |
NovelMed Therapeutics, Inc. |
Formulation of aglycosylated therapeutic antibodies
|
AU2016210918A1
(en)
|
2015-01-28 |
2017-07-13 |
Pfizer Inc., |
Stable aqueous anti- vascular endothelial growth factor (VEGF) antibody formulation
|
US10039826B2
(en)
|
2015-02-09 |
2018-08-07 |
Ucb Biopharma Sprl |
Pharmaceutical formulation comprising antibodies which bind colony stimulating factor-1 receptor (CSF1R)
|
RU2017131618A
(ru)
|
2015-02-13 |
2019-03-13 |
Санофи |
Стабильный жидкий состав для моноклональных антител
|
SG10201912035YA
(en)
|
2015-04-17 |
2020-02-27 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
KR101808234B1
(ko)
|
2015-06-23 |
2017-12-12 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
|
AU2016294332A1
(en)
|
2015-07-16 |
2017-11-30 |
Eli Lilly And Company |
Treatment of pruritus
|
IL257279B2
(en)
|
2015-08-19 |
2023-04-01 |
Medimmune Ltd |
Anti-Epner 1 formulation is stable
|
CN106474470B
(zh)
*
|
2015-08-28 |
2020-05-22 |
江苏恒瑞医药股份有限公司 |
一种抗il-17a抗体的组合物
|
TN2018000076A1
(en)
|
2015-09-09 |
2019-07-08 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
KR20200035496A
(ko)
|
2015-09-22 |
2020-04-03 |
화이자 인코포레이티드 |
치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형
|
JP6921062B2
(ja)
|
2015-09-28 |
2021-08-18 |
スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド |
安定な抗pd−1抗体医薬製剤および医薬におけるその適用
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
CN106620690A
(zh)
|
2015-10-30 |
2017-05-10 |
上海抗体药物国家工程研究中心有限公司 |
一种稳定的抗体制剂
|
CN108602881A
(zh)
|
2015-10-30 |
2018-09-28 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体制剂
|
AU2016356717B2
(en)
|
2015-11-18 |
2022-09-29 |
Sio2 Medical Products, Inc. |
Pharmaceutical package for ophthalmic formulations
|
US20190046641A1
(en)
|
2015-11-30 |
2019-02-14 |
Medimmune, Llc |
Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
|
US11058769B2
(en)
|
2015-12-07 |
2021-07-13 |
Merck Patent Gmbh |
Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
|
AU2016382786A1
(en)
|
2015-12-29 |
2018-07-19 |
Outlook Therapeutics, Inc. |
Buffered formulations of bevacizumab
|
RU2736830C2
(ru)
|
2016-01-12 |
2020-11-20 |
Др. Редди'С Лабораторис Лимитед |
Стабильная фармацевтическая композиция
|
SG11201805534TA
(en)
|
2016-01-13 |
2018-07-30 |
Genmab As |
Formulation for antibody and drug conjugate thereof
|
US10576128B2
(en)
|
2016-01-26 |
2020-03-03 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
MA46681A
(fr)
|
2016-01-28 |
2019-09-11 |
Janssen Biotech Inc |
Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
|
AR103622A1
(es)
|
2016-02-05 |
2017-05-24 |
Ucb Biopharma Sprl |
Formulación farmaceutica
|
JP7104629B2
(ja)
|
2016-02-24 |
2022-07-21 |
ビステラ, インコーポレイテッド |
インフルエンザウイルスに対する抗体分子の製剤
|
WO2017149513A1
(en)
|
2016-03-03 |
2017-09-08 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
TWI763660B
(zh)
|
2016-03-25 |
2022-05-11 |
美商威特拉公司 |
登革病毒的抗體分子之配方設計
|
JP6992262B2
(ja)
|
2016-03-31 |
2022-02-15 |
東ソー株式会社 |
変性抗体測定試薬の製造方法
|
EP3442503B1
(en)
|
2016-04-12 |
2023-03-15 |
Capsular Technologies Pty Ltd. |
Injectable composition for delivery of a biologically active agent
|
WO2017180594A1
(en)
|
2016-04-13 |
2017-10-19 |
Medimmune, Llc |
Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
|
GB201608323D0
(en)
|
2016-05-12 |
2016-06-29 |
Ucb Biopharma Sprl |
Pharmaceutical compositions
|
TWI826351B
(zh)
|
2016-05-31 |
2023-12-21 |
大陸商鴻運華寧(杭州)生物醫藥有限公司 |
R抗體,其藥物組合物及其應用
|
WO2017208210A1
(en)
|
2016-06-03 |
2017-12-07 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
EP3463317A4
(en)
|
2016-06-07 |
2020-01-08 |
Aridis Pharmaceuticals, Inc. |
PROCESS FOR THE PREPARATION OF FAST-DISSOLVING THIN FILMS CONTAINING A BIOLOGICALLY ACTIVE SUBSTANCE WITH IMPROVED THERMAL STABILITY
|
PT3475303T
(pt)
|
2016-06-27 |
2021-06-25 |
Morphosys Ag |
Formulações de anticorpos anti-cd19
|
MX2018015960A
(es)
|
2016-06-30 |
2019-03-21 |
Celltrion Inc |
Formulacion farmaceutica liquida estable.
|
CA3029642A1
(en)
|
2016-07-05 |
2018-01-11 |
Sanofi |
Antibody formulations
|
CN109476733A
(zh)
|
2016-07-19 |
2019-03-15 |
诺华股份有限公司 |
使用il-17拮抗剂治疗新发斑块型银屑病的方法
|
JOP20170170B1
(ar)
|
2016-08-31 |
2022-09-15 |
Omeros Corp |
صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
|
FR3056912B1
(fr)
|
2016-09-30 |
2019-12-27 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Procede d'inactivation virale d'une preparation d'anticorps monoclonaux
|
JP7275027B2
(ja)
|
2016-10-06 |
2023-05-17 |
アムジェン インコーポレイテッド |
粘度低下タンパク質医薬製剤
|
TW202237071A
(zh)
|
2016-10-07 |
2022-10-01 |
美商再生元醫藥公司 |
於室溫穩定之冷凍乾燥蛋白質
|
MY197200A
(en)
|
2016-12-23 |
2023-05-31 |
Serum Institute Of India Pvt Ltd |
Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
|
KR102471458B1
(ko)
|
2016-12-28 |
2022-11-25 |
제이씨알 파마 가부시키가이샤 |
동결건조 제제
|
WO2018122053A1
(en)
|
2016-12-29 |
2018-07-05 |
F. Hoffmann-La Roche Ag |
Anti-angiopoietin-2 antibody formulation
|
CN108261544B
(zh)
|
2016-12-30 |
2023-05-05 |
江苏太平洋美诺克生物药业股份有限公司 |
稳定的包含cd147单克隆抗体的药物制剂
|
CN108261391B
(zh)
|
2016-12-30 |
2022-03-01 |
江苏太平洋美诺克生物药业有限公司 |
稳定的包含cd147单克隆抗体的药物制剂
|
ES2933808T3
(es)
|
2017-01-11 |
2023-02-14 |
Celltrion Inc |
Fórmula líquida estable
|
LT3570884T
(lt)
|
2017-01-17 |
2020-12-10 |
Genentech, Inc. |
Poodinės her2 antikūnų kompozicijos
|
WO2018134184A1
(en)
|
2017-01-19 |
2018-07-26 |
Bayer Pharma Aktiengesellschaft |
Novel stable formulation for fxia antibodies
|
GB201703063D0
(en)
|
2017-02-24 |
2017-04-12 |
Arecor Ltd |
Stabilized antibody protein solutions
|
GB201703062D0
(en)
|
2017-02-24 |
2017-04-12 |
Arecor Ltd |
Stabilized antibody protein solutions
|
TWI761453B
(zh)
|
2017-03-01 |
2022-04-21 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
CN110366429A
(zh)
|
2017-03-01 |
2019-10-22 |
免疫医疗有限公司 |
单克隆抗体的配制品
|
MX2019010367A
(es)
|
2017-03-06 |
2019-12-02 |
Merck Patent Gmbh |
Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).
|
EP3372242A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
AU2018236651B2
(en)
|
2017-03-16 |
2020-12-10 |
Lg Chem, Ltd. |
Liquid formulation of anti-TNF alpha antibody
|
JPWO2018179138A1
(ja)
|
2017-03-29 |
2020-02-06 |
持田製薬株式会社 |
抗体含有液体製剤
|
EA201991912A1
(ru)
|
2017-03-29 |
2020-03-10 |
Селджин Корпорейшн |
Составы, содержащие pd-1-связывающие белки, и способы их получения
|
TW201836637A
(zh)
|
2017-03-29 |
2018-10-16 |
持田製藥股份有限公司 |
含有抗體之液體製劑
|
JP7179717B2
(ja)
|
2017-03-31 |
2022-11-29 |
Meiji Seikaファルマ株式会社 |
水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
JOP20190255A1
(ar)
|
2017-04-28 |
2019-10-27 |
Amgen Inc |
صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
|
CA3060581A1
(en)
|
2017-05-02 |
2018-11-08 |
Merck Sharp & Dohme Corp. |
Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
SG11202003754YA
(en)
|
2017-05-16 |
2020-05-28 |
Bhamis Research Laboratory Pvt Ltd |
High concentration protein formulations with reduced viscosity
|
EP3652205A1
(en)
|
2017-07-10 |
2020-05-20 |
Bayer Pharma Aktiengesellschaft |
Prolactin receptor antibody for male and female pattern hair loss
|
CN107400164A
(zh)
|
2017-07-18 |
2017-11-28 |
中山和芯生物技术有限公司 |
一种含蔗糖的生物制品稳定剂及其制备方法和应用
|
WO2019018640A1
(en)
|
2017-07-21 |
2019-01-24 |
Novartis Ag |
POSOLOGICAL REGIMES FOR ANTI-GITREN ANTIBODIES AND USES THEREOF
|
EP3658612A4
(en)
|
2017-07-25 |
2021-06-02 |
Elektrofi, Inc. |
TRAINING OF PARTICLES INCLUDING AGENTS
|
MX2020000582A
(es)
|
2017-07-27 |
2020-09-10 |
Jiangsu Hengrui Medicine Co |
Composicion farmaceutica de anticuerpos sost y usos de la misma.
|
CN110869050A
(zh)
|
2017-07-28 |
2020-03-06 |
豪夫迈·罗氏有限公司 |
双特异性抗体配制剂
|
WO2019036382A1
(en)
|
2017-08-15 |
2019-02-21 |
Progenity Inc. |
INFLAMMATORY DISEASE TREATMENT INVOLVING AN INGREDIENT DEVICE FOR RELEASING AN IMMUNOMODULATOR
|
AU2018320470A1
(en)
|
2017-08-23 |
2020-02-13 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate preparation and lyophilization for same
|
CA3074565A1
(en)
|
2017-09-05 |
2019-03-14 |
Merck Sharp & Dohme Corp. |
Compounds for reducing the viscosity of biological formulations
|
EP3459527B1
(en)
|
2017-09-20 |
2022-11-23 |
Tillotts Pharma Ag |
Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
|
WO2019064263A1
(en)
|
2017-09-29 |
2019-04-04 |
Janssen Biotech, Inc. |
NOVEL FORMULATIONS FOR STABILIZING LOW DOSE ANTIBODY COMPOSITIONS
|
JP7170983B2
(ja)
|
2017-10-13 |
2022-11-15 |
国立大学法人大阪大学 |
改善された保存安定性を有するタンパク質含有液体製剤およびその製造方法
|
CN109745559A
(zh)
|
2017-11-01 |
2019-05-14 |
三生国健药业(上海)股份有限公司 |
抗人il-17a的单克隆抗体的液体制剂
|
GB201718888D0
(en)
|
2017-11-15 |
2017-12-27 |
Ucb Biopharma Sprl |
Method
|
GB201719447D0
(en)
|
2017-11-23 |
2018-01-10 |
Ucb Biopharma Sprl |
Pharmaceutical composition
|
KR20200090164A
(ko)
|
2017-11-29 |
2020-07-28 |
프로테나 바이오사이언시즈 리미티드 |
트랜스타이레틴에 대한 단클론성 항체의 동결건조 제형
|
IL297354A
(en)
|
2017-11-30 |
2022-12-01 |
Bio Thera Solutions Ltd |
A liquid preparation of a humanized antibody for the treatment of 6-il-related disease
|
CA3085656A1
(en)
|
2017-12-22 |
2019-06-27 |
Jiangsu Hengrui Medicine Co., Ltd. |
Lag-3 antibody pharmaceutical composition and use thereof
|
EP3749363A1
(en)
|
2018-02-08 |
2020-12-16 |
Amgen Inc. |
Low ph pharmaceutical antibody formulation
|
MX2020009275A
(es)
|
2018-03-07 |
2021-01-08 |
Pfizer |
Composiciones de anticuerpo anti-pd-1.
|
US11427639B2
(en)
|
2018-04-02 |
2022-08-30 |
Richter Gedeon Nyrt. |
Antibody-containing aqueous formulation and use thereof
|
JP7442823B2
(ja)
|
2018-04-06 |
2024-03-05 |
シプルメット・ゲーエムベーハー |
治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
MA52657A
(fr)
|
2018-04-10 |
2021-02-17 |
Genmab As |
Anticorps spécifiques d'axl pour le traitement du cancer
|
KR20210011923A
(ko)
|
2018-04-17 |
2021-02-02 |
아웃룩 테라퓨틱스, 인크. |
질환 치료 용도를 위한 베바시주맙의 완충 제제
|
JP2021522209A
(ja)
|
2018-04-25 |
2021-08-30 |
メディミューン リミテッド |
ヒト抗pd−l1抗体の配合物
|
US11103552B2
(en)
|
2018-05-10 |
2021-08-31 |
Regeneron Pharmaceuticals, Inc. |
High concentration VEGF receptor fusion protein containing formulations
|
AU2019269131B2
(en)
|
2018-05-14 |
2024-02-22 |
Fundació Privada Institució Catalana De Recerca I Estudis Avançats |
Antibodies against LIF and dosage forms thereof
|
CN110538321B
(zh)
|
2018-05-29 |
2023-03-10 |
江苏恒瑞医药股份有限公司 |
一种cd47抗体药物组合物及其用途
|
AU2019276572A1
(en)
|
2018-06-01 |
2020-12-24 |
Rakuten Medical, Inc. |
Phthalocyanine dye conjugate compositions
|
US20210223262A1
(en)
|
2018-06-07 |
2021-07-22 |
Merck Sharp & Dohme Corp. |
Lyosphere critical reagent kit
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
US20230009902A1
(en)
|
2018-06-20 |
2023-01-12 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue orginating from the endoderm
|
EP3810095A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
US20230033021A1
(en)
|
2018-06-20 |
2023-02-02 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
EP3810268A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
EP3880233A1
(en)
|
2018-06-22 |
2021-09-22 |
Bioralix B.V. |
Formulations of biological polymers for oral administration
|
WO2020004368A1
(ja)
|
2018-06-25 |
2020-01-02 |
Jcrファーマ株式会社 |
蛋白質含有水性液剤
|
TW202011995A
(zh)
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
US20210169896A1
(en)
|
2018-07-05 |
2021-06-10 |
Hangzhou Dac Biotech Co., Ltd. |
A cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates
|
EP3823594A1
(en)
|
2018-07-19 |
2021-05-26 |
Ichnos Sciences S.A. |
Liquid antibody formulation
|
KR20200010103A
(ko)
|
2018-07-19 |
2020-01-30 |
(주)셀트리온 |
안정한 액체 약제학적 제제
|
US11396542B2
(en)
|
2018-08-21 |
2022-07-26 |
Synkrino Biotherapeutics, Inc. |
Astrotactin1-based compositions and pharmaceutical formulations
|
WO2020053301A1
(en)
|
2018-09-11 |
2020-03-19 |
Ichnos Sciences S.A. |
Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents
|
KR20210062027A
(ko)
|
2018-09-13 |
2021-05-28 |
에프. 호프만-라 로슈 아게 |
Csf-1r 항체 제제
|
KR20210074286A
(ko)
|
2018-10-05 |
2021-06-21 |
파이브 프라임 테라퓨틱스, 인크. |
항-fgfr2 항체 제형
|
MX2021004146A
(es)
|
2018-10-10 |
2021-06-08 |
Astellas Pharma Inc |
Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
|
NZ775656A
(en)
|
2018-10-12 |
2023-11-24 |
Hangzhou Dac Biotech Co Ltd |
Conjugation linkers containing 2,3-diaminosuccinyl group
|
MX2021004356A
(es)
|
2018-10-18 |
2021-05-31 |
Merck Sharp & Dohme Llc |
Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
|
WO2020087003A1
(en)
|
2018-10-26 |
2020-04-30 |
Amgen Inc. |
Formulations comprising a tris buffer and a protein
|
CR20210200A
(es)
|
2018-10-29 |
2021-05-25 |
Hoffmann La Roche |
Formulación de anticuerpos
|
MX2021005015A
(es)
|
2018-10-31 |
2021-07-21 |
Richter Gedeon Nyrt |
Formulaciones farmaceuticas acuosas.
|
KR20210124959A
(ko)
|
2018-11-06 |
2021-10-15 |
젠맵 에이/에스 |
항체 제제
|
WO2020097141A1
(en)
|
2018-11-07 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
|
CN113164378A
(zh)
|
2018-11-21 |
2021-07-23 |
瑞泽恩制药公司 |
高浓度蛋白质制剂
|
EP3890778A4
(en)
|
2018-12-03 |
2022-08-03 |
Agensys, Inc. |
PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY CONJUGATES - MEDICINES AND METHODS OF USING THE SAME
|
EP3893841A1
(en)
|
2018-12-14 |
2021-10-20 |
MorphoSys AG |
Antibody formulations
|
MX2021008267A
(es)
|
2019-01-08 |
2021-08-05 |
H Lundbeck As |
Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp.
|
EP3914689A2
(en)
|
2019-01-25 |
2021-12-01 |
SiO2 Medical Products, Inc. |
Common contact surfaces for use in the manufacture, packaging, delivery, and assessment of biopharmaceutical products
|
CN113423430A
(zh)
|
2019-01-31 |
2021-09-21 |
杭州多禧生物科技有限公司 |
含支链连接子的鹅膏毒素偶联物
|
CN113365609A
(zh)
|
2019-01-31 |
2021-09-07 |
伊勒卓菲公司 |
颗粒形成和形态
|
UA128098C2
(uk)
|
2019-02-18 |
2024-04-03 |
Елі Ліллі Енд Компані |
Водна фармацевтична композиція антитіла проти il-17a
|
TW202102260A
(zh)
|
2019-03-21 |
2021-01-16 |
美商再生元醫藥公司 |
含有抗il-33抗體之穩定調配物
|
CN113365665A
(zh)
|
2019-03-26 |
2021-09-07 |
荣昌生物制药(烟台)股份有限公司 |
抗Her2抗体药物偶联物药物制剂
|
CN113660953A
(zh)
|
2019-04-01 |
2021-11-16 |
豪夫迈·罗氏有限公司 |
用于稳定含蛋白质制剂的组合物和方法
|
MA55559A
(fr)
|
2019-04-04 |
2022-02-09 |
Janssen Biotech Inc |
Procédé d'administration d'un anticorps anti-ifn-alpha/-oméga
|
SG11202110942SA
(en)
|
2019-04-18 |
2021-11-29 |
Janssen Biotech Inc |
Sialylated glycoproteins
|
WO2020223565A1
(en)
|
2019-05-01 |
2020-11-05 |
Corvidia Therapeutics, Inc. |
Anti-il-6 antibody formulation
|
CN110179746A
(zh)
|
2019-05-17 |
2019-08-30 |
通化东宝生物科技有限公司 |
一种稳定的苏金单抗注射剂及其制备方法
|
WO2020233534A1
(zh)
|
2019-05-17 |
2020-11-26 |
百奥泰生物制药股份有限公司 |
抗体-药物偶联物制剂、制备方法及应用
|
JP2022532928A
(ja)
|
2019-05-24 |
2022-07-20 |
サノフイ |
全身性硬化症を治療するための方法
|
AU2020282792A1
(en)
|
2019-05-28 |
2021-12-23 |
Banner Health |
ApoE antibodies, fusion proteins and uses thereof
|
TW202112354A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
US11655302B2
(en)
|
2019-06-10 |
2023-05-23 |
Sanofi |
Anti-CD38 antibodies and formulations
|
CN110124030A
(zh)
|
2019-06-10 |
2019-08-16 |
通化东宝生物科技有限公司 |
一种苏金单抗注射液及其制备方法
|
CN114245737A
(zh)
|
2019-06-11 |
2022-03-25 |
司斐股份有限公司 |
微乳剂组合物
|
MX2021015887A
(es)
|
2019-06-24 |
2022-03-22 |
Hangzhou Dac Biotech Co Ltd |
Un conjugado de un agente citotóxico y una molécula de unión a células con enlazadores ramificados.
|
WO2021013689A1
(en)
|
2019-07-19 |
2021-01-28 |
Ichnos Sciences SA |
Lyophilized antibody formulation
|
EP3766481A1
(en)
|
2019-07-19 |
2021-01-20 |
Ichnos Sciences SA |
Liquid antibody formulation
|
CN112805566A
(zh)
|
2019-07-29 |
2021-05-14 |
上海谷森医药有限公司 |
用于吸入治疗肺癌的抗体类药物制剂
|
JP2022547546A
(ja)
|
2019-09-13 |
2022-11-14 |
エレクトロフィ,インコーポレイテッド |
疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法
|
JP2022549200A
(ja)
|
2019-09-20 |
2022-11-24 |
ノバルティス アーゲー |
インターロイキン-17(il-17)アンタゴニストを使用して自己免疫疾患を治療する方法
|
CN110585430B
(zh)
|
2019-09-29 |
2023-09-08 |
华博生物医药技术(上海)有限公司 |
一种人源化抗人il-17a单克隆抗体的药物组合物
|
CN114786719A
(zh)
|
2019-10-02 |
2022-07-22 |
阿拉玛布治疗学股份有限公司 |
抗-连接蛋白抗体制剂
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
CN112891530B
(zh)
|
2020-06-19 |
2021-08-24 |
北京东方百泰生物科技股份有限公司 |
一种抗il-17ra单克隆抗体的注射制剂
|